Core Viewpoint - A class action lawsuit has been announced by Rosen Law Firm on behalf of purchasers of Vistagen Therapeutics, Inc. common stock during the specified Class Period from April 1, 2024, to December 16, 2025, with a lead plaintiff deadline of March 16, 2026 [1]. Group 1: Lawsuit Details - The lawsuit claims that Vistagen provided misleading information regarding its drug fasedienol, which is under development for treating social anxiety disorder, while making overly positive assertions about its trial success based on previous results [5][6]. - Defendants allegedly concealed material adverse facts about the Phase 3 PALISADE-3 trial, leading to investor damages when the true information became public [6]. Group 2: Participation Information - Investors who purchased Vistagen common stock during the Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][7].

Company Overview - Immunovant, Inc. is a clinical-stage immunology company focused on developing therapies for autoimmune diseases, utilizing anti-FcRn technology to create targeted treatments [3]. Financial Results Announcement - Immunovant will report its financial results for the third quarter ending December 31, 2025, and provide a business update on February 6, 2026, at 8:00 a.m. ET [1]. Conference Call Access - Investors can access the conference call by registering online, with details available on Immunovant's website under the "News & Events" section [2].

As filed with the Securities and Exchange Commission on January 23, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AKARI THERAPEUTICS, PLC (Exact name of registrant as specified in its charter) England and Wales 2834 98-1034922 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code) (I.R.S. Employer Identification No.) 401 East Jackson ...

NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the “Class Period”), of the important March 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Vistagen common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fe ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Jan. 26, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present 3-year topline functional results from patients treated in Part 1 of EMBARK (Study 9001-301), the global, randomized placebo-controlled Phase 3 study evaluating ELEVIDYS (delandistrogene moxeparvovec-rokl) in ambulatory individuals with Du ...

SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has closed its previously announced upsized public offering of 25,875,000 shares of its common stock, including 3,375,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The shares of com ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Markets have quickly recovered from their one-day sell-off Tuesday that saw the S&P 500 and NASDAQ fall over 2% on the day. However, tensions quickly de-escalated on Wednesday following a speech by the POTUS at Davos. Over the next two ...

Group 1: Voya MidCap Opportunities Fund Overview - The Voya MidCap Opportunities Fund's Q4 2025 investor letter highlights solid market gains but notes relative underperformance against the Russell Mid Cap Growth Index due to unfavorable stock selection [1] - The fund managers maintain a cautiously constructive outlook, emphasizing the importance of active and flexible positioning amid ongoing geopolitical risks and policy uncertainty [1] - The letter indicates that broadening market leadership, sustained corporate capital expenditure, and AI-led innovation could support future returns [1] Group 2: Vera Therapeutics, Inc. Performance - Vera Therapeutics, Inc. was a top contributor to the fund's performance in Q4 2025, driven by positive phase three clinical trial results for its kidney disease treatment [3] - At the end of Q4 2025, Vera Therapeutics represented 0.93% of the fund's portfolio, with a one-month return of -9.09% and a trading range of $18.53 to $56.05 over the past 52 weeks [2] - As of January 22, 2026, Vera Therapeutics' stock closed at approximately $45.77 per share, with a market capitalization of about $3.249 billion [2] Group 3: Hedge Fund Interest and Market Position - Vera Therapeutics was held by 36 hedge fund portfolios at the end of Q3 2025, a decrease from 40 in the previous quarter [4] - The investment community acknowledges the risks and potential of Vera Therapeutics but expresses a stronger conviction in AI stocks for higher returns in a shorter timeframe [4]

Core Viewpoint - Cardiol Therapeutics Inc. has successfully completed a private placement of units, raising a total of $14.85 million to support its research and clinical development programs for heart disease therapies [1][3]. Financing Details - The company issued 11,423,078 units at a price of $1.30 per unit, which includes the full exercise of the over-allotment option by the underwriter [1]. - Each unit consists of one Class A common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of one common share at an exercise price of $1.75 for 24 months [2]. - The underwriter received a cash commission of 6% of the aggregate gross proceeds from the offering [2]. Use of Proceeds - The net proceeds from the financing will be utilized to advance research and clinical development programs, as well as for general administrative expenses and working capital [3]. Regulatory Compliance - The offering was conducted as a private placement under National Instrument 45-106, allowing sales to qualified investors in Canada, excluding Quebec [4]. - The units issued are not subject to resale restrictions in Canada under applicable securities laws [4]. Company Overview - Cardiol Therapeutics is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate, CardiolRx™, targeting inflammation and fibrosis associated with heart conditions [6]. - The company is conducting the MAVERIC Program to evaluate CardiolRx™ for recurrent pericarditis and has received Orphan Drug Designation from the U.S. FDA for this treatment [7]. - Additionally, the ARCHER Program is studying CardiolRx™ for acute myocarditis, a significant cause of heart failure in young adults [8]. - Cardiol is also developing CRD-38, a novel subcutaneous drug formulation for inflammatory heart disease, addressing a major healthcare cost issue in the U.S. [9].

RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially announced on October 14, 2025. The transaction strengthens its position as a leader in hereditary angioedema (HAE) and enhances the company’s long-term growth trajectory. BioCryst adds navenibart, a late-stage, long-acting plasma kallikrein inhibitor currently in Phase 3 clinical development, to its HAE por ...